Superworth

Coherus Oncology EV/EBIT CHRS

Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2020.

Today, Oct 23, 2026
n/m
an operating loss
Last meaningful
6.1×
Apr 2021
Peer median
11.9×

Coherus Oncology has no meaningful EV/EBIT today: it made an operating loss of $158.7M over the last twelve months.

It was last meaningful in Apr 2021, at 6.1×.

EV/EBIT over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
20216.1×5.7×6.8×
20206.3×5.7×11.8×

Against its peers

Companies in Healthcare nearest Coherus Oncology's size, closest first, today.

CompanyEV/EBIT
CHRSCoherus Oncologyn/m
PDEXPro DEX16.0×
PLXProtalix BioTherapeutics7.5×
NATRNatures Sunshine Products5.2×
ELMDElectromed14.4×
UTMDUtah Medical Products6.0×
KEQUKewaunee Scientific7.2×
ICCCImmucell14.2×
INFUInfuSystem22.4×
LFVNLifevantage9.6×
VMDViemed Healthcare16.3×
Peer median11.9×

What the EV/EBIT tells you

What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.

Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.

More on Coherus Oncology

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.